Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid.
The majority of IgG elimination occurs via intracellular
catabolism, following fluid-phase or receptor mediated
endocytosis.
